(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
2025 Arctic League telethon raises more than $39k - 2Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- 3Overlooked infertility care should be part of national health services, says WHO
- 4The most effective method to Recognize a Great Lab Jewel
- 5Real time features for Films and Programs
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- Top 15 Style Creators Changing the Business
- Figure out How to Explore Land Close to 5G Pinnacles
- Instructions to Explore the Universe of Vehicle Leases
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
